CTI Anticipates Preliminary Data From Pivotal Pixantrone Trial In Mid-2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is forging ahead with non-Hodgkin’s lymphoma program following positive special protocol assessment from FDA.